keyword
MENU ▼
Read by QxMD icon Read
search

Disease-modifying antirheumatic drugs

keyword
https://www.readbyqxmd.com/read/28339004/cyclocurcumin-a-curcumin-derivative-exhibits-immune-modulating-ability-and-is-a-potential-compound-for-the-treatment-of-rheumatoid-arthritis-as-predicted-by-the-mm-pbsa-method
#1
Min Fu, Lihui Chen, Limin Zhang, Xiao Yu, Qingrui Yang
The control and treatment of rheumatoid arthritis is a challenge in today's world. Therefore, the pursuit of natural disease-modifying antirheumatic drugs (DMRDs) remains a top priority in rheumatology. The present study focused on curcumin and its derivatives in the search for new DMRDs. We focused on prominent p38 mitogen-activated protein (MAP) kinase p38α which is a prime regulator of tumor necrosis factor-α (TNF-α), a key mediator of rheumatoid arthritis. In the present study, we used the X-ray crystallographic structure of p38α for molecular docking simulations and molecular dynamic simulations to study the binding modes of curcumin and its derivatives with the active site of p38α...
March 20, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28336154/socioeconomic-and-therapy-factor-influence-on-self-reported-fatigue-anxiety-and-depression-in-rheumatoid-arthritis-patients
#2
Mirjana Lapčević, Mira Vuković, Branislav S Gvozdenović, Vesna Mioljević, Snežana Marjanović
INTRODUCTION: Fatigue, anxiety and depression are very frequent symptoms in patients with rheumatoid arthritis (RA). GOALS: In this study we evaluated the influence of socioeconomic characteristics, therapy and comorbidities on the self-reported high fatigue, anxiety and depression in patients with RA. METHOD: Multicenter cross-sectional study was performed in 22 health institutions in Serbia during the period from April-August 2014 in population of older RA patients...
February 27, 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28331376/long-term-safety-and-efficacy-of-biosimilar-infliximab-among-patients-with-inflammatory-arthritis-switched-from-reference-product
#3
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O'Sullivan, Ann Maria Curran, John J Carey
PURPOSE: To evaluate the efficacy and safety of the biosimilar infliximab in adult patients with inflammatory arthritis switched from reference product in our center. PATIENTS AND METHODS: In April 2014, patients attending our rheumatology service for infliximab infusions were switched from reference product to the biosimilar infliximab following consent and hospital approval. RESULTS: Around 34 patients with inflammatory arthritis were switched from reference product to biosimilar infliximab in 2014: 50% female, mean age 55 years (standard deviation=12...
2017: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/28326189/sarilumab-improves-patient-reported-outcomes-in-rheumatoid-arthritis-patients-with-inadequate-response-intolerance-to-tumour-necrosis-factor-inhibitors
#4
Vibeke Strand, Matthew Reaney, Chieh-I Chen, Clare W J Proudfoot, Sophie Guillonneau, Deborah Bauer, Erin Mangan, Neil M H Graham, Hubert van Hoogstraten, Yong Lin, César Pacheco-Tena, Roy Fleischmann
OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitors (TNF-IR). METHODS: 546 patients (81.9% female, mean age 52.9 years) were randomised to placebo, sarilumab 150 or 200 mg subcutaneously every 2 weeks + csDMARDs...
2017: RMD Open
https://www.readbyqxmd.com/read/28324149/-outpatient-care-and-disease-burden-of-rheumatoid-arthritis-results-of-a%C3%A2-linkage-of-claims-data-and-a%C3%A2-survey-of-insured-persons
#5
K Albrecht, A Luque Ramos, J Callhoff, F Hoffmann, K Minden, A Zink
BACKGROUND: Healthcare of patients with rheumatoid arthritis (RA) in Germany has mainly been evaluated in the past in RA cohorts from specialized arthritis centers. This study investigated rheumatological care on a population basis, using claims data from a nationwide statutory health insurance fund (BARMER GEK) in combination with patient-reported outcomes from a questionnaire survey of insured persons with RA. METHODS: Data from insurants aged 18-79 years with M05 (seropositive RA) or M06 (other RA, ICD-10) diagnoses were analyzed concerning diagnostics, medication and prescribing physician...
March 21, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28301793/advances-in-rheumatoid-arthritis
#6
Graeme Jones, Peter Nash, Stephen Hall
There are now eight approved biological disease-modifying antirheumatic drugs (bDMARDs), two biosimilars and one targeted synthetic DMARD in Australia with a number of new products and biosimilars in the pipeline. bDMARDs have excellent efficacy, especially when combined with traditional DMARDs, and a well characterised but manageable safety profile. These expanded therapeutic options have revolutionised patient care and made remission (including drug free remission) a realistic goal. Evidence of a "window of opportunity" that changes the long term phenotype of the disease has been well established, so therapy should be commenced as early as possible in the disease process and a shared care model between general practitioner and rheumatologist provides the best outcomes...
March 20, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28298374/safety-of-synthetic-and-biological-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-management-of-rheumatoid-arthritis
#7
Sofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, Jackie L Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Johannes W Bijlsma, Gerd R Burmester, Marieke Scholte-Voshaar, Louise Falzon, Robert B M Landewé
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included...
March 15, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28296761/polymorphisms-and-pharmacogenomics-for-the-toxicity-of-methotrexate-monotherapy-in-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis
#8
Qi Qiu, Jing Huang, Yang Lin, Xiaoming Shu, Huizheng Fan, Zhihua Tu, Youwen Zhou, Cheng Xiao
BACKGROUND: Methotrexate (MTX) is widely used and considered a first-line disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, 10% to 30% of patients discontinue therapy within a year of starting the treatment, usually because of undesirable side effects. Many of the relevant genes have been investigated to estimate the association between gene polymorphisms and MTX toxicity in RA patients, although inconsistent results have been reported...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28294642/cost-effectiveness-of-sequenced-treatment-of-rheumatoid-arthritis-with-targeted-immune-modulators
#9
Jeroen P Jansen, Devin Incerti, Alex Mutebi, Desi Peneva, Joanna MacEwan, Bradley Stolshek, Primal Kaur, Mahdi Gharaibeh, Vibeke Strand
AIMS: To determine the cost-effectiveness of treatment sequences of biologic disease-modifying antirheumatic drugs or Janus kinase/STAT pathway inhibitors (collectively referred to as bDMARDs) versus conventional DMARDs (cDMARDs) from the US societal perspective for treatment of patients with moderately to severely active rheumatoid arthritis (RA) with inadequate responses to cDMARDs. MATERIALS AND METHODS: We developed an individual patient simulation model that assesses the impact of treatments on disease based on clinical trial data and real-world evidence...
March 15, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28293115/topical-medication-utilization-and-health-resources-consumption-in-adult-patients-affected-by-psoriasis-findings-from-the-analysis-of-administrative-databases-of-local-health-units
#10
Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti
AIM: The objectives of this study were to: 1) analyze the drug utilization pattern among adult psoriasis patients who were newly prescribed with topical medication; and 2) assess their adherence to topical therapy and the possibility of switching to other strategies in the treatment process. METHODS: An observational retrospective analysis was conducted based on administrative databases of two Italian local health units. All adult subjects who were diagnosed with psoriasis or who were newly prescribed for topical medication with at least one prescription between January 1, 2010, and December 31, 2014, were screened...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28289873/patient-reported-outcomes-as-predictors-of-remission-in-early-rheumatoid-arthritis-patients-treated-with-tight-control-treat-to-target-approach
#11
Laura Kuusalo, Kari Puolakka, Hannu Kautiainen, Anna Karjalainen, Timo Malmi, Timo Yli-Kerttula, Marjatta Leirisalo-Repo, Vappu Rantalaiho
Identifying prognostic factors for remission in early rheumatoid arthritis (ERA) patients is of key clinical importance. We studied patient-reported outcomes (PROs) as predictors of remission in a clinical trial. We randomized 99 untreated ERA patients to receive remission-targeted treatment with three disease-modifying antirheumatic drugs and prednisolone for 24 months, and infliximab or placebo for the initial 6 months. At baseline, we measured following PROs: eight Short Form 36 questionnaire (SF-36) dimensions, patient's global assessment [PGA, visual analogue scale (VAS)], Health Assessment Questionnaire (HAQ), and pain VAS...
March 13, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28288972/interleukin-6-inhibition-and-coronary-artery-disease-in-a-high-risk-population-a-prospective-community-based-clinical-study
#12
Bruno Cesar Bacchiega, Ana Beatriz Bacchiega, Magali Justina Gomez Usnayo, Ricardo Bedirian, Gurkirpal Singh, Geraldo da Rocha Castelar Pinheiro
BACKGROUND: Atherosclerosis is a chronic inflammatory disease, with interleukin 6 (IL-6) as a major player in inflammation cascade. IL-6 blockade may reduce cardiovascular risk, but current treatments to block IL-6 also induce dyslipidemia, a finding with an uncertain prognosis. METHODS AND RESULTS: We aimed to determine the endothelial function responses to the IL-6-blocking agent tocilizumab, anti-tumor necrosis factor α, and synthetic disease-modifying antirheumatic drug therapies in patients with rheumatoid arthritis in a 16-week prospective study...
March 13, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#13
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28279189/therapeutic-strategies-of-drug-repositioning-targeting-autophagy-to-induce-cancer-cell-death-from-pathophysiology-to-treatment
#14
REVIEW
Go J Yoshida
The 2016 Nobel Prize in Physiology or Medicine was awarded to the researcher that discovered autophagy, which is an evolutionally conserved catabolic process which degrades cytoplasmic constituents and organelles in the lysosome. Autophagy plays a crucial role in both normal tissue homeostasis and tumor development and is necessary for cancer cells to adapt efficiently to an unfavorable tumor microenvironment characterized by hypo-nutrient conditions. This protein degradation process leads to amino acid recycling, which provides sufficient amino acid substrates for cellular survival and proliferation...
March 9, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28277784/association-between-mthfr-c677t-polymorphism-and-methotrexate-treatment-outcome-in-rheumatoid-arthritis-patients-a-systematic-review-and-meta-analysis
#15
Wenjing Shao, Yi Yuan, Yuying Li
PURPOSE: Methotrexate (MTX) is one of the most widely used disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis (RA). However, its efficacy in RA patients is variable and unpredictable. Methylene tetrahydrofolate reductase (MTHFR) is an important enzyme in the MTX pathway and is involved in folate metabolism and DNA synthesis. Several studies have examined the association between the MTHFR C677T polymorphism and MTX toxicity and efficacy in RA, but their conclusions remain controversial...
March 9, 2017: Genetic Testing and Molecular Biomarkers
https://www.readbyqxmd.com/read/28277344/use-of-hydroxychloroquine-is-associated-with-improved-lipid-profile-in-rheumatoid-arthritis-patients
#16
Jose Felix Restrepo, Inmaculada Del Rincon, Emily Molina, Daniel F Battafarano, Agustin Escalante
BACKGROUND/PURPOSE: We examined the association between hydroxychloroquine (HCQ) and plasma lipid and glucose levels in rheumatoid arthritis (RA) cohort. METHODS: This is a retrospective cohort analysis of 1261 RA patients comparing fasting lipid profiles and plasma glucose between patients who were and were not taking HCQ. We divided patients into 3 groups based on HCQ exposure during follow-up: those who had never taken HCQ, those who took it intermittently, and those who took it continuously...
April 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28271947/health-assessment-questionnaire-disability-index-haq-di-score-at-the-start-of-biological-disease-modifying-antirheumatic-drug-bdmard-therapy-is-associated-with-radiographic-progression-of-large-joint-damage-in-patients-with-rheumatoid-arthritis
#17
Arata Nakajima, Yasuchika Aoki, Keiichiro Terayama, Masato Sonobe, Hiroshi Takahashi, Masahiko Saito, Koichi Nakagawa
OBJECTIVES: Radiographic progression of damage (RPD) to large joints in patients with rheumatoid arthritis (RA) has not been fully studied. We previously demonstrated that Larsen grade of the large joints was associated with RPD of large joints in patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs); however, no factors associated with background characteristics of patients were identified. METHODS: A total of 400 large joints in the upper and lower extremities, including the shoulder, elbow, knee, and ankle, of 88 patients with RA treated with bDMARDs for 1-3 years were investigated...
March 8, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28270933/no-impact-of-concomitant-methotrexate-use-on-serious-adverse-event-and-serious-infection-risk-in-patients-with-rheumatoid-arthritis-treated-with-bdmards-a-systematic-literature-review-and-meta-analysis
#18
Claire Baradat, Yannick Degboé, Arnaud Constantin, Alain Cantagrel, Adeline Ruyssen-Witrand
OBJECTIVES: To compare the risk of serious adverse events, serious infections and death caused by methotrexate and biological disease-modifying antirheumatic drug (bDMARD) combination therapy versus a bDMARD prescribed as monotherapy in rheumatoid arthritis (RA). METHODS: A systematic literature review was conducted until February 2016 in PubMed, Embase and Cochrane Library databases by selecting randomised controlled trials comparing methotrexate and bDMARD combination therapy to bDMARD monotherapy in RA...
2017: RMD Open
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#19
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
March 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28259568/chloroquine-improves-the-response-to-ischemic-muscle-injury-and-increases-hmgb1-after-arterial-ligation
#20
Jun Xu, Xiangdong Cui, Jiehua Li, Panagiotis Koutakis, Iraklis Pipinos, Edith Tzeng, Alex Chen, Ulka Sachdev
OBJECTIVE: We have previously shown that exogenous administration of the nuclear protein high mobility group box 1 (HMGB1) improves angiogenesis after tissue ischemia. Antagonizing HMGB1 prolongs muscle necrosis and deters regeneration. In this study, we evaluated HMGB1 expression in peripheral arterial disease (PAD) and the mechanisms that promote its release in a murine model of hindlimb ischemia. Specifically, we investigated how chloroquine (CQ), a commonly employed disease-modifying antirheumatic drug, promotes HMGB1 release from muscle...
March 1, 2017: Journal of Vascular Surgery
keyword
keyword
116670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"